DDInter856 DDInter969
Unfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (factor IIa) and factor Xa. UH is different from low molecular weight heparin (LMWH) in the following ways: the average molecular weight of LMWH is about 4.5 kDa whereas it is 15 kDa for UH; UH requires continuous infusions; activated partial prothrombin time (aPTT) monitoring is required when using UH; and UH has a higher risk of bleeding and higher risk of osteoporosis in long term use. Unfractionated hepar
Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.[A35065,A35080,L12126] Ipilimumab was developed by Bristol-Myers Squibb and Medarex. Ipilimumab was granted FDA approval on 25 March 2011.
Ipilimumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Budesonide
Ipilimumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enfortumab vedotin
Ipilimumab {u} may lead to a major life threatening interaction when taken with {v} Apixaban
Ipilimumab {u} may lead to a major life threatening interaction when taken with {v} Ardeparin
Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Budesonide
Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Ipilimumab may lead to a major life threatening interaction when taken with Apixaban
Ipilimumab may lead to a major life threatening interaction when taken with Ardeparin